Bristol-Myers collaboarate with Simcere Pharmaceuticals for development and commercialization of subcutaneous formulation of Bristol-Myer Squibb's RA drug Orencia

BMY and Simcere pharmaceuticals have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.